A three-dose course of AstraZeneca’s Covid-19 vaccine is effective against the rapidly spreading Omicron coronavirus variant, the pharmaceutical company said on December 23, citing data from an Oxford University lab study.

A new study shows the persistent syndrome of Covid-19 after-effects known as long Covid can develop after “breakthrough” infections in vaccinated people. Other new findings suggest a gene that helps the coronavirus reproduce itself might contribute to life-threatening Covid-19 in young, otherwise healthy people.

A study out of Oxford University’s Leverhulme Centre for Demographic Science found that the Covid-19 pandemic has resulted in the largest drop in life expectancy in western Europe since World War II.

The Covid-19 pandemic reduced life expectancy in 2020 by the largest amount since World War Two, according to a study published on Sept. 27 by Oxford University, with the life expectancy of American men dropping by more than two years.

A study published in The Lancet Infectious Diseases found that the Pfizer-BioNTech, Oxford-AstraZeneca or Moderna vaccines resulted in a drop in “long-haul” Covid-19 by 50 percent. According to data collected by the American Academy of Pediatrics (AAP), more than 500,000 children tested positive in the United States for Covid-19 from August 5 to August 26.

In line with growing concerns that certain Covid-19 vaccines are causing unusual blood clotting problems, a group of scientists from the U.K. conducted a massive study on the link between vaccinations and dropping platelet counts and found that the problem lies more on the virus itself than on the medications. 

A group of scientists from the Nuffield Department of Women’s & Reproductive Health at Oxford University may have found a potential key to finally treating endometriosis, a disease that affects around 176 million women worldwide. 

A British public health study found that protection from either of the two most commonly used Covid-19 vaccines against the prevalent Delta variant of the coronavirus weakens within three months.

Second-quarter 2021 sales of AstraZeneca’s Covid-19 vaccine more than tripled to $894 million from the first quarter, but the drugmaker on July 29 again delayed the U.S. application for approval as the company gathers more data for submissions.

AstraZeneca’s Covid-19 vaccine carries a small extra risk of rare blood clots with low platelets after the first dose and no extra risk after the second, a study led and funded by the drugmaker showed on July 28, after worries over side effects.